Literature DB >> 33326098

Analysis of Regulatory DNA Sequences by Dual-Luciferase Reporter Assays in Ewing Sarcoma.

Tilman L B Hölting1, Maximilian M L Knott2,3.   

Abstract

Reporter gene assays allow for examining the influence of regulatory DNA sequences on the transcription of target genes. In Ewing sarcoma, the study of these DNA sequences is especially paramount for its main driver mutation is a fusion transcription factor that binds different motifs than its wild-type constituents. Here, we describe the process of analyzing the enhancer activity of regulatory DNA sequences using transfection-based dual-luciferase reporter assays in Ewing sarcoma cell lines. To this end, we provide a protocol for cloning sequences of interest from genomic DNA into a firefly luciferase-containing plasmid, transfecting Ewing sarcoma cells with plasmids and measuring luciferase expression by luminescence. The entire procedure can be completed in 14 days.

Entities:  

Keywords:  Enhancer activity; Ewing sarcoma; Fusion-driven sarcoma; Gene expression; Luciferase assay; Promoter activity; Regulatory DNA; Regulatory sequence; Reporter assays

Mesh:

Substances:

Year:  2021        PMID: 33326098     DOI: 10.1007/978-1-0716-1020-6_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

1.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours.

Authors:  O Delattre; J Zucman; B Plougastel; C Desmaze; T Melot; M Peter; H Kovar; I Joubert; P de Jong; G Rouleau
Journal:  Nature       Date:  1992-09-10       Impact factor: 49.962

Review 2.  Firefly luciferase as a tool in molecular and cell biology.

Authors:  S J Gould; S Subramani
Journal:  Anal Biochem       Date:  1988-11-15       Impact factor: 3.365

Review 3.  Ewing sarcoma.

Authors:  Thomas G P Grünewald; Florencia Cidre-Aranaz; Didier Surdez; Eleni M Tomazou; Enrique de Álava; Heinrich Kovar; Poul H Sorensen; Olivier Delattre; Uta Dirksen
Journal:  Nat Rev Dis Primers       Date:  2018-07-05       Impact factor: 52.329

4.  Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.

Authors:  Thomas G P Grünewald; Virginie Bernard; Pascale Gilardi-Hebenstreit; Virginie Raynal; Didier Surdez; Marie-Ming Aynaud; Olivier Mirabeau; Florencia Cidre-Aranaz; Franck Tirode; Sakina Zaidi; Gaëlle Perot; Anneliene H Jonker; Carlo Lucchesi; Marie-Cécile Le Deley; Odile Oberlin; Perrine Marec-Bérard; Amélie S Véron; Stephanie Reynaud; Eve Lapouble; Valentina Boeva; Thomas Rio Frio; Javier Alonso; Smita Bhatia; Gaëlle Pierron; Geraldine Cancel-Tassin; Olivier Cussenot; David G Cox; Lindsay M Morton; Mitchell J Machiela; Stephen J Chanock; Patrick Charnay; Olivier Delattre
Journal:  Nat Genet       Date:  2015-07-27       Impact factor: 38.330

5.  Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma.

Authors:  Kirsten M Johnson; Cenny Taslim; Ranajeet S Saund; Stephen L Lessnick
Journal:  PLoS One       Date:  2017-11-01       Impact factor: 3.240

6.  Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes.

Authors:  Julian Musa; Florencia Cidre-Aranaz; Marie-Ming Aynaud; Martin F Orth; Maximilian M L Knott; Olivier Mirabeau; Gal Mazor; Mor Varon; Tilman L B Hölting; Sandrine Grossetête; Moritz Gartlgruber; Didier Surdez; Julia S Gerke; Shunya Ohmura; Aruna Marchetto; Marlene Dallmayer; Michaela C Baldauf; Stefanie Stein; Giuseppina Sannino; Jing Li; Laura Romero-Pérez; Frank Westermann; Wolfgang Hartmann; Uta Dirksen; Melissa Gymrek; Nathaniel D Anderson; Adam Shlien; Barak Rotblat; Thomas Kirchner; Olivier Delattre; Thomas G P Grünewald
Journal:  Nat Commun       Date:  2019-09-11       Impact factor: 14.919

  6 in total
  1 in total

1.  Circular RNA SOX5 promotes the proliferation and inhibits the apoptosis of the hepatocellular carcinoma cells by targeting miR-502-5p/synoviolin 1 axis.

Authors:  Yu Cai; Yuanyuan Jia
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.